Cefepime vs. conventional combination therapy for PD-associated peritonitis
Intraperitoneal cefepime monotherapy is noninferior to conventional combination therapy for resolution of continuous ambulatory peritoneal dialysis-associated peritonitis.
A new randomized controlled study evaluated whether intraperitoneal (IP) cefepime monotherapy is noninferior to combination regimens for continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis. Results showed that IP cefepime monotherapy was noninferior to conventional combination therapy for resolution of CAPD-associated peritonitis at day 10 and may be a reasonable alternative first-line treatment.
Find out more here